首都医科大学学报 ›› 2004, Vol. 25 ›› Issue (2): 223-226.

• 论著·临床研究 • 上一篇    下一篇

2型糖尿病合并冠心病患者纤溶酶原激动抑制剂-1基因多态性分析

王旭东1, 樊峥2, 傅研1, 殷红2, 翟艳玲3, 祁雅慧2, 朱宇清1, 王瑾1, 赵相印3   

  1. 1. 首都医科大学附属北京同仁医院急诊科;2. 首都医科大学实验中心;3. 北京同仁医院血液科
  • 收稿日期:2003-04-21 修回日期:1900-01-01 出版日期:2004-04-15 发布日期:2004-04-15

4G/5G Polymorphism at Plasminogen Activator Inhibitor-1 Promoter in Patients with Type Ⅱ Diabetic and Coronary Artery Disease

Wang Xudong1, Fan Zheng2, Fu Yan1, Yin Hong2, Zhai Yanling3, Qi Yahui2, Zhu Yuqing1, Wang Jin1, Zhao Xiangyin3   

  1. 1. Department of Emergency, Beijing Tongren Hospital, Affiliate of Capital University of Medical Sciences;2. Experimental Center, Capital University of Medical Science;3. Department of Hematology, Beijing Tongren Hospital
  • Received:2003-04-21 Revised:1900-01-01 Online:2004-04-15 Published:2004-04-15

摘要: 为探讨纤溶酶原激活抑制剂-1(PAI-1)基因调节区-675 bp位点4G/5G多态性与2型糖尿病、2型糖尿病合并冠心病(CAD)的关系,采用特异性引物聚合酶链反应(PCR)方法,测定4G/5G基因型,并检测PAI-1抗原水平,共观察了121例单纯2型糖尿病(type Ⅱ diab etes)患者、87例2型糖尿病合并CAD患者和100例对照者.结果:合并CAD组的4G/4G基因型携带者明显高于对照组(49.4%比 37.0%,P<0.05),CAD组中PAI-1与三酰甘油(TG)呈正相关,并与4G/5G多态性有关, 表现为4G/4G基因型携带者的PAI-1质量浓度明显高于5G/5G基因型携带者[(39.82×10-3±3.11×10-3)ng/L比(38.04×10-3± 2.73 ×10-3)ng/L,P<0.05].提示:PAI-1基因4G/5G多态性与TG的联合作用与PA I-1抗原水平相关,并与2型糖尿病合并CAD的发病过程有关.

关键词: 纤溶酶原激活抑制剂-1, 基因多态性, 2型糖尿病, 冠心病

Abstract: The aim was to investigate the genotype at a plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism in patients with type Ⅱ diabetes and complicated coronary artery disease(CAD). The level of PAI-1 antigen was measured and the 4G/5G polymorphism genotype was determined by polymerase chain reaction(PCR) amplification of genomic DNA using the allele specific primers in Chinese type Ⅱ diabetes subjects(121 type Ⅱ diabetes patients, 87 diabetic patients with CAD) and 100 control subjects. The frequency of the 4G/4G genotype increased and that of the 5G/5G genotype decreased in group of diabetic CAD compared with control subjects(49.4% vs. 37.0%, P< 0.05). The level of PAI-1 antigen was positively correlated with levels of triglyceride(P<0.001) and associated with 4G/5G polymorphism (P=0.03). PAI-1 antigen level was significantly higher in 4G/4G genotype carriers than in 5G/5G genotype carriers in group of CAD 〔(39.82×10-3 ±3.11×10-3)ng/L vs (38.04× 10-3±2.73×10-3)ng/L, P<0.05〕. This polymorphic variation at PAI-1 promoter interacts with risk factors of triglyceride when associated with increased level of PAI-1 antigen and pathogenesis of CAD in type Ⅱ diabetes.

Key words: plasminogen activator inhibitor-1, gene polymorphism, type Ⅱ diabetes, coronary artery disease

中图分类号: